NovoSeven® Resolved 96.5% of Bleeds When Initiated Within One Hour After Bleed Onset in People With Haemophilia A or B With Inhibitors - Seite 2
About NovoSeven®
NovoSeven® is a recombinant activated factor VII (rFVIIa) and is indicated for the treatment of spontaneous and surgical bleedings in haemophilia A or B patients with inhibitors, acquired haemophilia, congenital FVII deficiency and Glanzmann's thrombasthenia (EU and US only).[8]
About haemophilia
Haemophilia is a chronic, inherited bleeding disorder that primarily affects males. People born with haemophilia have little or no clotting factor, which is a protein needed for normal blood clotting. The two main types of haemophilia are A and B; people living with haemophilia A lack clotting factor VIII and people living with haemophilia B lack clotting factor IX. Haemophilia A is about four times as common as haemophilia B.[9] Inhibitor formation is the most serious complication in haemophilia A or B, rendering the patient unresponsive of replacement therapy with clotting factor VIII or IX. In that case, bypassing agents such as NovoSeven® are used.
Haemophilia can be mild, moderate or severe, depending on the amount of clotting factor in the blood. Approximately 400,000 people are estimated to live with haemophilia globally.[10]
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,600 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Lesen Sie auch
Further information
Media:
Katrine Sperling
+45 4442 6718
krsp@novonordisk.com
Åsa Josefsson
+45 3079 7708
aajf@novonordisk.com
Investors:
Peter Hugreffe Ankersen
+45 3075 9085
phak@novonordisk.com
Melanie Raouzeos
+45 3075 3479
mrz@novonordisk.com
Anders Mikkelsen
+45 3079 4461
armk@novonordisk.com
Hannah Ögren
+45 3075 8519
haoe@novonordisk.com
Kasper Veje (US)
+1 609 235 8567
kpvj@novonordisk.com
References
- Benson, G. et al. Benefit of early treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in patients with Hemophilia A or B with inhibitors: Subgroup Analysis from the Prospective, Post-Authorization, Non-interventional SMART-7™ Study. Poster number 1439. 58th American Society of Haematology (ASH) annual meeting. 3 December 2016.
- Lusher JM. Eur J Haematol 1998;61(suppl 63):7-10.
- Santagostino E, et al. Blood Rev 2015;29(suppl 1):S9-18.
- Santagostino E, et al. J Thromb Haemost 2006;4(2):367-71.
- Young G, et al. Haemophilia. 2008 Mar;14(2):287-94.
- Kavakli K, et al. Thromb Haemost 2006;95(4):600-5.
- Lentz SR, et al. J Thromb Haemost 2014;12(8):1244-53.
- NovoSeven® Summary of Product Characteristics.
- National Heart Lung and Blood Institute. What is hemophilia? https://www.nhlbi.nih.gov/health/health-topics/topics/hemophilia (last accessed October 2016).
- National Hemophilia Foundation. Fast Facts. http://www.hemophilia.org/About-Us/Fast-Facts (last accessed November 2016).